Albiflorin on Neuropsychiatric and Neurodegenerative Disorders: A Systematic Review

IF 5 1区医学 Q1 NEUROSCIENCES

CNS Neuroscience & Therapeutics Pub Date : 2025-07-25 DOI:10.1111/cns.70535

Shasha Sun, Hamizah Shahirah Hamezah, Chuanshan Jin, Rongchun Han, Xiaohui Tong

{"title":"Albiflorin on Neuropsychiatric and Neurodegenerative Disorders: A Systematic Review","authors":"Shasha Sun, Hamizah Shahirah Hamezah, Chuanshan Jin, Rongchun Han, Xiaohui Tong","doi":"10.1111/cns.70535","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Albiflorin, a key compound from <i>Paeonia lactiflora</i>, has shown therapeutic potential in neuropsychiatric and neurodegenerative disorders (NPDs and NDDs), especially depression and Alzheimer's disease (AD). This review aimed to summarize its pharmacological effects, mechanisms, pharmacokinetics, and therapeutic prospects.</p>\n </section>\n \n <section>\n \n <h3> Discussion</h3>\n \n <p>Albiflorin exhibits multi-target actions, including modulation of monoamine neurotransmitters, inhibition of neuroinflammation, and enhancement of neuroplasticity. In AD, it reduces Aβ accumulation, improves mitochondrial function, and activates MAPK/ERK and Nrf2/HO-1 signaling pathways. In depression, it restores phospholipid and tryptophan metabolism, regulates HPA axis function, and increases BDNF expression. Albiflorin crosses the blood-brain barrier (BBB) and may act indirectly via the gut-brain axis through its metabolite benzoic acid. Though brain concentrations are low, its pharmacological effects remain significant. Albiflorin also shows potential benefits in conditions like cerebral ischemia and hypoxic-ischemic brain injury. Toxicological data indicate low systemic toxicity and good safety margins <i>in vivo</i> and <i>in vitro</i>.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Albiflorin demonstrates promising therapeutic potential for NPDs and NDDs via multi-pathway regulation. However, further studies are needed to optimize brain delivery, understand gut microbiota interactions, and confirm efficacy through clinical trials. The advancement of formulation strategies and pharmacokinetic research will be considered key to achieving clinical translation.</p>\n </section>\n </div>","PeriodicalId":154,"journal":{"name":"CNS Neuroscience & Therapeutics","volume":"31 7","pages":""},"PeriodicalIF":5.0000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cns.70535","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Neuroscience & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cns.70535","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

Albiflorin, a key compound from Paeonia lactiflora, has shown therapeutic potential in neuropsychiatric and neurodegenerative disorders (NPDs and NDDs), especially depression and Alzheimer's disease (AD). This review aimed to summarize its pharmacological effects, mechanisms, pharmacokinetics, and therapeutic prospects.

Discussion

Albiflorin exhibits multi-target actions, including modulation of monoamine neurotransmitters, inhibition of neuroinflammation, and enhancement of neuroplasticity. In AD, it reduces Aβ accumulation, improves mitochondrial function, and activates MAPK/ERK and Nrf2/HO-1 signaling pathways. In depression, it restores phospholipid and tryptophan metabolism, regulates HPA axis function, and increases BDNF expression. Albiflorin crosses the blood-brain barrier (BBB) and may act indirectly via the gut-brain axis through its metabolite benzoic acid. Though brain concentrations are low, its pharmacological effects remain significant. Albiflorin also shows potential benefits in conditions like cerebral ischemia and hypoxic-ischemic brain injury. Toxicological data indicate low systemic toxicity and good safety margins in vivo and in vitro.

Conclusions

Albiflorin demonstrates promising therapeutic potential for NPDs and NDDs via multi-pathway regulation. However, further studies are needed to optimize brain delivery, understand gut microbiota interactions, and confirm efficacy through clinical trials. The advancement of formulation strategies and pharmacokinetic research will be considered key to achieving clinical translation.

Abstract Image

查看原文本刊更多论文

Albiflorin对神经精神和神经退行性疾病的系统评价

目的芍药苷（Albiflorin）是芍药中的一种重要化合物，具有治疗神经精神和神经退行性疾病（npd和ndd），特别是抑郁症和阿尔茨海默病（AD）的潜力。现就其药理作用、机制、药代动力学及治疗前景作一综述。Albiflorin具有多靶点作用，包括调节单胺类神经递质、抑制神经炎症和增强神经可塑性。在AD中，它减少了Aβ的积累，改善了线粒体功能，激活了MAPK/ERK和Nrf2/HO-1信号通路。在抑郁症中，它恢复磷脂和色氨酸代谢，调节HPA轴功能，增加BDNF表达。Albiflorin通过血脑屏障（BBB），并通过其代谢物苯甲酸间接作用于肠脑轴。虽然在大脑中的浓度很低，但其药理作用仍然显著。Albiflorin在脑缺血和缺氧缺血性脑损伤等情况下也显示出潜在的益处。毒理学数据表明，体内和体外系统毒性低，安全性好。结论Albiflorin通过多途径调控npd和ndd，具有良好的治疗潜力。然而，需要进一步的研究来优化大脑递送，了解肠道微生物群的相互作用，并通过临床试验确认疗效。配方策略和药代动力学研究的进步将被认为是实现临床转化的关键。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

CNS Neuroscience & Therapeutics 医学-神经科学

CiteScore

7.30

自引率

12.70%

发文量

240

审稿时长

2 months

期刊介绍： CNS Neuroscience & Therapeutics provides a medium for rapid publication of original clinical, experimental, and translational research papers, timely reviews and reports of novel findings of therapeutic relevance to the central nervous system, as well as papers related to clinical pharmacology, drug development and novel methodologies for drug evaluation. The journal focuses on neurological and psychiatric diseases such as stroke, Parkinson’s disease, Alzheimer’s disease, depression, schizophrenia, epilepsy, and drug abuse.